Source: Annual Congress 2007 - Mouse models of allergic airway inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Saraya, D. Kurai, H. Wada, H. Ishii, S. Horie, K. Iihara, Y. Fujioka, S. Kurata, H. Taguchi, S. Kamiya, T. Oka, T. Akashi, K. Nakagaki, K. Nakata, H. Goto (Mitaka, Tokyo, Tokyo, Saitama, Niigata, Japan). Immunomodulating effect of clarithromycin in a murine model of mycoplasma pneumoniae pneumonia. Eur Respir J 2007; 30: Suppl. 51, 4341

Member's Comments

No comment yet.

Related content which might interest you: Comparison of immunomodulating effects among clarithromycin, dexamethasone and levofloxacin on the murine model of mycoplasma pneumoniae pneumonia Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Co-treatment with clarithromycin and dexamethasone on murine mycoplasma pneumoniae pneumonia model Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009 Treatment of patients with bronchial asthma and latent chlamydophila pneumoniae and mycoplasma pneumoniae infections by a doxycycline Source: Eur Respir J 2002; 20: Suppl. 38, 159s Year: 2002 Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia Source: Eur Respir J 2010; 36: 969-971 Year: 2010 The efficacies of macrolides in a murine model of methicillin-resistant staphylococcus aureus hematogenous pulmonary infection Source: Eur Respir J 2002; 20: Suppl. 38, 357s Year: 2002 Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection in which Streptococcus pyogenes was isolated in sputum culture Source: Eur Respir J 2004; 24: Suppl. 48, 414s Year: 2004 Streptococcus pneumoniae is the main causative agent of community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 608s Year: 2002 Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model Source: Eur Respir J 2005; 25: 693-700 Year: 2005 Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002 Telavancin vs. linezolid in an animal model of severe MRSA pneumonia Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae Source: Eur Respir J 2006; 27: 1020-1025 Year: 2006 Peculiarities of community-acquired pneumonia course, caused by multiresistant strains of S. pneumoniae Source: Eur Respir J 2006; 28: Suppl. 50, 165s Year: 2006 Streptococcus pneumoniae resistance pattern and its clinical implications Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Levofloxacin resistance among streptococcus pneumoniae isolates in a chronic disease hospital Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 Monitoring of Mycoplasma pneumoniae and Chlamydia pneumoniae in young patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 140s Year: 2001 Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004 Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis Source: Eur Respir J 2007; 29: 1127-1137 Year: 2007 Severe Chlamydia pneumoniae community-acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 545s Year: 2003 Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia Source: Eur Respir J 2001; 17: 241-245 Year: 2001